SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout!
LGND 206.36+1.4%Nov 26 3:59 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Machaon who wrote (23757)7/31/1998 2:09:00 PM
From: J Stone  Read Replies (1) of 32384
 
Re: Targretin trails for Diabetes.

I thought Henry, or one of the other biochem. types, commented a few months back that there was a potentially problematic issue with Targetin raising levels of a particular metabolic element above the healthful limit. My recollection was that Targretin may not be the Type II diabetes savior people were hoping for because of this; however, I believe Ligand has next generation compounds related to Targretin that should offer safer profiles. Of course, my recollections relating to Targretin could be quite faulty. The one thing I do know is that human renal systems are very similar to mouse renal systems, so that if Targretin effectively handled Type II diabetes well in mice there's a 99% probability it would do the same in humans barring the matter of undesired side-effects.

FWIW

Jeff
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext